Advertisement
Table 1 Baseline characteristics of patients with unresectable hepatocellular carcinoma who underwent either HAIC or TACE
| Variable | HAIC [cases (%)] | TACE [cases (%)] | P |
|---|---|---|---|
| Total | 38 | 41 | |
| Age (years) | 0.638 | ||
| ≤ 60 | 27 (71.1) | 27 (65.9) | |
| > 60 | 11 (28.9) | 14 (34.1) | |
| Gender | 0.215 | ||
| Male | 30 (78.9) | 37 (90.2) | |
| Female | 8 (21.1) | 4 (9.8) | |
| Tumor size (cm) | 1.000 | ||
| < 10 | 12 (31.6) | 12 (29.3) | |
| ≥ 10 | 26 (68.4) | 29 (70.7) | |
| Tumor number | 0.654 | ||
| ≤ 3 | 18 (47.4) | 17 (41.5) | |
| > 3 | 20 (52.6) | 24 (58.5) | |
| BCLC stage | 0.338 | ||
| A | 15 (39.5) | 11 (26.8) | |
| B | 23 (60.5) | 30 (73.2) | |
| Liver cirrhosis | 0.368 | ||
| No | 20 (52.6) | 26 (63.4) | |
| Yes | 18 (47.4) | 15 (36.6) | |
| Neutrophil: lymphocyte ratio | 0.361 | ||
| ≤ 3 | 22 (57.9) | 28 (68.3) | |
| > 3 | 16 (42.1) | 13 (31.7) | |
| Hemoglobin (g/L) | 1.000 | ||
| < 100 | 1 (2.6) | 1 (2.4) | |
| ≥ 100 | 37 (97.4) | 40 (97.6) | |
| Platelet count | 1.000 | ||
| < 100 × 109/L | 1 (2.6) | 2 (4.9) | |
| ≥ 100 × 109/L | 37 (97.4) | 39 (95.1) | |
| Hepatitis B surface antigen | 0.434 | ||
| Negative | 2 (5.3) | 5 (12.2) | |
| Positive | 36 (94.7) | 36 (87.8) | |
| HBV DNA (IU/mL) | 0.593 | ||
| ≤ 1000 | 10 (26.3) | 8 (19.5) | |
| > 1000 | 28 (73.7) | 33 (80.5) | |
| PT (s) | 0.003 | ||
| ≤ 13.5 | 28 (73.7) | 40 (97.6) | |
| > 13.5 | 10 (26.3) | 1 (2.4) | |
| ALT (U/L) | 1.000 | ||
| ≤ 40 | 17 (44.7) | 18 (43.9) | |
| > 40 | 21 (55.3) | 23 (56.1) | |
| ALB (g/L) | 0.655 | ||
| ≤ 40 | 20 (52.6) | 19 (46.3) | |
| > 40 | 18 (47.4) | 22 (53.7) | |
| TBIL (μmol/L) | 0.284 | ||
| ≤ 20.5 | 27 (71.1) | 34 (82.9) | |
| > 20.5 | 11 (28.9) | 7 (17.1) | |
| AFP (ng/mL) | 0.813 | ||
| ≤ 400 | 12 (31.6) | 15 (36.6) | |
| > 400 | 26 (68.4) | 26 (63.4) | |
